Custom service
Peptide Drug AI Design and Screening Platform
Couple ai-driven design with the screening infrastructure to close the loop
The service is built around generative sequence design. Depending on the molecule we may move to predictive property filtering or closed-loop test-and-learn to improve stability, loading or yield, and every batch is released with design-screen iteration report with leads.
Because Peptide Drug AI Design and Screening Platform projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.
Programmes needing many design rounds
Multi-property optimization problems
One-off designs without an iteration budget
Targets with no assayable readout and no purified protein available
Screening programmes close with a data package: primary screen statistics, confirmation data for each hit, counterscreen results and resynthesized material. Library lots ship with composition QC — representation and identity checks by LC-MS or NGS as the format requires.
Service Highlights
- Generative sequence design as the default route, with predictive property filtering held as a proven fallback
- Closed-loop test-and-learn worked into the design where the application requires it
- Every reported hit is confirmed by independent resynthesis and re-testing before it reaches you
- Analytical confirmation of every intermediate before the final release
- Library integrity (composition, representation) is measured, not assumed, before screening begins
- Design-screen iteration report with leads delivered with a complete conjugation or synthesis certificate
How the work runs
Library design
Diversity, degeneracy and deconvolution strategy for Peptide Drug AI Design and Screening Platform are fixed in a design document.
Library synthesis or construction
The library is built with generative sequence design and its composition is QC'd before screening.
Primary screening
Screening runs with predictive property filtering, with controls and statistics defined in advance.
Hit deconvolution
Hits are identified and ranked; counterscreens remove non-specific and promiscuous binders.
Hit confirmation
Every hit is resynthesized and re-tested; only reproducible hits advance.
Hit delivery
Confirmed hits and Design-screen iteration report with leads are delivered with the full screening data package.
Specifications & timeline
- Turnaround
- 8–14 weeks
- Typical scale
- 10^2 – 10^9 members by format
- Chemistry options
- generative sequence design; predictive property filtering; closed-loop test-and-learn
- Deliverable
- Design-screen iteration report with leads
- QC package
- Library composition QC, screening raw data, hit confirmation package
- Shipping
- Ambient (plates, beads) or dry ice (display libraries)
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.